Literature DB >> 28585864

Sustained release effects of berberine-loaded chitosan microspheres on in vitro chondrocyte culture.

Yan Zhou1, Shiqing Liu1, Jianghua Ming1, Yaming Li1, Ming Deng1, Bin He1.   

Abstract

The low bioavailability and short biological half-life of berberine chloride (BBR) negatively affect the protective role of this compound against osteoarthritis (OA). The present study was performed to evaluate the effectiveness of sustained BBR release system. Novel BBR-loaded chitosan microspheres (BBR-loaded CMs) were successfully synthesized using an ionic cross-linking method for sustained release. The basic characteristics of the prepared microspheres were subsequently evaluated by scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FT-IR), X-ray diffraction (XRD) techniques, encapsulation efficiency (EE), and in vitro release experiments. BBR-loaded CMs displayed spherical forms to encapsulate a considerable quantity of BBR (100.8 ± 2.7 mg/g); these microspheres also exhibited an ideal releasing profile. The FT-IR spectra and XRD results revealed that BBR-loaded CMs were successfully synthesized via electrostatic interaction. In vitro experiments further showed that BBR-loaded CMs significantly inhibited sodium nitroprusside (SNP)-stimulated chondrocyte apoptosis as well as cytoskeletal remodeling, and led to increasing mitochondrial membrane potential and maintaining the nuclear morphology. BBR-loaded CMs exerted markedly higher anti-apoptotic activity in the treatment of OA, and markedly inhibited the protein expression levels of caspase-3, a disintegrin, and metalloproteinase with thrombospondin motifs (ADAMTS)-5 and matrix metalloproteinase (MMP)-13 induced by SNP in rat articular chondrocytes, compared with free BBR at equivalent concentration. Therefore, novel BBR-loaded CMs may offer potential for application in the treatment of OA.

Entities:  

Keywords:  Chitosan; berberine; composite microspheres; drug release; osteoarthritis

Mesh:

Substances:

Year:  2017        PMID: 28585864     DOI: 10.1080/03639045.2017.1339076

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  6 in total

1.  Mucus-Penetrating Alginate-Chitosan Nanoparticles Loaded with Berberine Hydrochloride for Oral Delivery to the Inflammation Site of Ulcerative Colitis.

Authors:  Lingfeng Sun; Xiangjiang Nie; Wenjie Lu; Qing Zhang; Wenyou Fang; Song Gao; Shengqi Chen; Rongfeng Hu
Journal:  AAPS PharmSciTech       Date:  2022-06-27       Impact factor: 4.026

2.  Comparative pharmacokinetics and safety assessment of transdermal berberine and dihydroberberine.

Authors:  Beth Buchanan; Qingfang Meng; Mathieu-Marc Poulin; Jonathan Zuccolo; Chike Godwin Azike; Joseph Gabriele; David Charles Baranowski
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

Review 3.  The Quest to Enhance the Efficacy of Berberine for Type-2 Diabetes and Associated Diseases: Physicochemical Modification Approaches.

Authors:  Solomon Habtemariam
Journal:  Biomedicines       Date:  2020-04-18

4.  Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial.

Authors:  Jessica M Moon; Kayla M Ratliff; Anthony M Hagele; Richard A Stecker; Petey W Mumford; Chad M Kerksick
Journal:  Nutrients       Date:  2021-12-28       Impact factor: 5.717

5.  Effects of Berberine on the Chondrogenic Differentiation of Embryonic Limb Skeletal Progenitors.

Authors:  Cristina Duarte-Olivenza; Juan Antonio Montero; Carlos Ignacio Lorda-Diez
Journal:  J Inflamm Res       Date:  2021-09-29

Review 6.  Botanical Drug Extracts Combined With Biomaterial Carriers for Osteoarthritis Cartilage Degeneration Treatment: A Review of 10 Years of Research.

Authors:  Panyun Mu; Jie Feng; Yimei Hu; Feng Xiong; Xu Ma; Linling Tian
Journal:  Front Pharmacol       Date:  2022-01-31       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.